NZ592400A - Transition metal complexes of bis[thiohydrazide amide] compounds - Google Patents

Transition metal complexes of bis[thiohydrazide amide] compounds

Info

Publication number
NZ592400A
NZ592400A NZ592400A NZ59240009A NZ592400A NZ 592400 A NZ592400 A NZ 592400A NZ 592400 A NZ592400 A NZ 592400A NZ 59240009 A NZ59240009 A NZ 59240009A NZ 592400 A NZ592400 A NZ 592400A
Authority
NZ
New Zealand
Prior art keywords
bis
transition metal
compounds
thiohydrazide amide
metal complexes
Prior art date
Application number
NZ592400A
Other languages
English (en)
Inventor
Masazumi Nagai
Jianhua Shen
Original Assignee
Synta Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp filed Critical Synta Pharmaceuticals Corp
Publication of NZ592400A publication Critical patent/NZ592400A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • C07C327/38Amides of thiocarboxylic acids
    • C07C327/56Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00Thiocarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/83Thioacids; Thioesters; Thioamides; Thioimides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/08Copper compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Furan Compounds (AREA)
NZ592400A 2008-10-22 2009-10-21 Transition metal complexes of bis[thiohydrazide amide] compounds NZ592400A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19693208P 2008-10-22 2008-10-22
PCT/US2009/061480 WO2010048284A1 (en) 2008-10-22 2009-10-21 Transition metal complexes of bis[thiohydrazide amide] compounds

Publications (1)

Publication Number Publication Date
NZ592400A true NZ592400A (en) 2013-09-27

Family

ID=42119652

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ592400A NZ592400A (en) 2008-10-22 2009-10-21 Transition metal complexes of bis[thiohydrazide amide] compounds

Country Status (13)

Country Link
US (1) US9174935B2 (enExample)
EP (1) EP2349991A4 (enExample)
JP (2) JP2012506443A (enExample)
KR (1) KR20110073613A (enExample)
CN (1) CN102256937B (enExample)
AU (1) AU2009308502B2 (enExample)
BR (1) BRPI0919720A2 (enExample)
CA (1) CA2741189A1 (enExample)
IL (1) IL212439A (enExample)
MX (1) MX2011004276A (enExample)
NZ (1) NZ592400A (enExample)
WO (1) WO2010048284A1 (enExample)
ZA (1) ZA201103015B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
KR20110073613A (ko) 2008-10-22 2011-06-29 신타 파마슈티칼스 코프. 비스(티오하이드라자이드 아마이드) 화합물의 전이금속착체
US8461199B2 (en) * 2008-10-22 2013-06-11 Synta Pharmaceuticals Corp. Transition metal complexes of a bis[thio-hydrazide amide] compound
CA2745065A1 (en) 2008-12-01 2010-06-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2011069159A2 (en) * 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
WO2011133673A1 (en) 2010-04-20 2011-10-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
EP2776021A1 (en) 2011-11-10 2014-09-17 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
WO2013103795A1 (en) 2012-01-05 2013-07-11 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers
JP6660712B2 (ja) * 2015-11-10 2020-03-11 株式会社Screenホールディングス 分類器構成方法および細胞の生死判定方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS583499B2 (ja) 1975-07-28 1983-01-21 旭化成株式会社 アンテイカサレタ ポリウレタンソセイブツ
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
ES2430373T3 (es) 2004-06-23 2013-11-20 Synta Pharmaceuticals Corp. Sales de bis(tio-hidrazida amida) para tratamiento de cánceres
US20060142393A1 (en) 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
WO2006062732A2 (en) 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
AU2005306471B2 (en) 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
NZ562572A (en) 2005-04-15 2011-01-28 Synta Pharmaceuticals Corp Combination cancer therapy with BIS (thiohydrazide) amide compounds
WO2006113572A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
NZ563124A (en) 2005-05-16 2010-12-24 Synta Pharmaceuticals Corp Synthesis of bis(thio-hydrazide amide) salts
CA2618723C (en) * 2005-08-16 2014-05-27 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
EP2059236A2 (en) 2006-08-21 2009-05-20 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
JP2010501563A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
TW200817371A (en) 2006-08-21 2008-04-16 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders
WO2008024305A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
US20080176828A1 (en) 2006-08-21 2008-07-24 Martin Williams Treating melanoma with BIS(THIOHYDRAZIDE AMIDES)
JP2010502616A (ja) 2006-08-31 2010-01-28 シンタ ファーマシューティカルズ コーポレーション 癌を治療するためのビス(チオヒドラジドアミド)の組み合わせ
EP2061430A2 (en) 2006-09-11 2009-05-27 Synta Pharmaceuticals Corporation Bis (thiohydrazide amides) formulation
TW200829543A (en) 2006-09-15 2008-07-16 Synta Pharmaceuticals Corp Purification of bis(thiohydrazide amides)
US20090093538A1 (en) 2007-01-03 2009-04-09 Synta Pharmaceuticals Corp Method for treating cancer
US8093425B2 (en) 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8729111B2 (en) 2007-08-07 2014-05-20 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
EP2225201A2 (en) 2007-11-28 2010-09-08 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
KR20110073613A (ko) 2008-10-22 2011-06-29 신타 파마슈티칼스 코프. 비스(티오하이드라자이드 아마이드) 화합물의 전이금속착체
US8461199B2 (en) 2008-10-22 2013-06-11 Synta Pharmaceuticals Corp. Transition metal complexes of a bis[thio-hydrazide amide] compound
CA2745065A1 (en) 2008-12-01 2010-06-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2011069159A2 (en) * 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia

Also Published As

Publication number Publication date
JP5886986B2 (ja) 2016-03-16
US9174935B2 (en) 2015-11-03
MX2011004276A (es) 2011-06-27
JP2012506443A (ja) 2012-03-15
AU2009308502B2 (en) 2013-08-01
JP2015120708A (ja) 2015-07-02
ZA201103015B (en) 2012-01-25
IL212439A (en) 2015-01-29
WO2010048284A1 (en) 2010-04-29
KR20110073613A (ko) 2011-06-29
EP2349991A4 (en) 2014-06-04
BRPI0919720A2 (pt) 2015-12-08
CN102256937A (zh) 2011-11-23
US20110294877A1 (en) 2011-12-01
IL212439A0 (en) 2011-06-30
CN102256937B (zh) 2014-12-17
EP2349991A1 (en) 2011-08-03
CA2741189A1 (en) 2010-04-29
AU2009308502A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
NZ592400A (en) Transition metal complexes of bis[thiohydrazide amide] compounds
IN2009KN02409A (enExample)
MX352731B (es) Derivados de heteroarilpiperidina y -piperazina como fungicidas.
MX2009003256A (es) Inhibidor de la activacion de stat3/5.
WO2008078800A1 (ja) 金属錯体、高分子化合物及びこれらを含む素子
TW200621704A (en) Anti-bacterial compounds
UA99908C2 (ru) Пиридопиразиновые производные, способ борьбы с растениями, гербицидные композиции
UA96152C2 (en) Dihydropyrazolopyrimidinone derivatives
BRPI0712163A2 (pt) composto, e, agente antimicrobiano
WO2009041514A1 (ja) 染毛用染料及び染毛用組成物
IL204621A (en) Amino Acid Derivatives - γ - In bicycles preparations containing them and their uses
MX2009003073A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk.
MX2008010070A (es) Uso de compuestos de metales complejos como catalizadores de oxidacion.
MX350993B (es) Composiciones para el cuidado personal que comprenden una piritiona y un quelante de hierro.
MX2010004893A (es) Compuesto heterociclico y composicion farmaceutica del mismo.
IN2014DN10723A (enExample)
MX2010010660A (es) Nuevos complejos de rutenio como catalizadores para reacciones de metatesis.
WO2009047298A3 (en) Dimers of harmol or of its derivatives and uses thereof
SG144807A1 (en) Double metal cyanide catalysts for the preparation of polyether polyols
CO6321284A2 (es) Compuestos triciclicos que contienen nitrogeno y su uso como antibacteriales
MY146514A (en) Diarylether derivatives as antitumor agents
MD3655F1 (en) Inhibitor of human myeloid leukemia on base of bis(2-hydroxy-8-phenyl-tricyclo/7.3.1.0.2,7/-tridecane-13-on-thiosemicarbazonato)
MD3890F1 (en) Inhibitors of human myeloid leukemia on base of coordinative compounds of copper(II) with salicylidene thiocarbazides
PL374113A1 (en) Use of transition metal complexes with nitrogen-containing polydentate ligands as a bleaching catalyst and bleaching agent composition
MY155903A (en) Antitumor agent

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 OCT 2016 BY DAVIES COLLISON CAVE

Effective date: 20140108

LAPS Patent lapsed